Compare Prudential PLC (PUK) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs 10X Genomics Inc — how do they compare? Prudential PLC trades at $29.47 (market cap $35.71B), while 10X Genomics Inc trades at $46.82 (market cap $5.48B). The key difference: Prudential PLC is far larger — about 6.5× 10X Genomics Inc's market cap, and Prudential PLC pays a 1.84% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| PUK | TXG | |
|---|---|---|
Market Cap | $35.71B | $5.48B |
Sector | Financials | Health |
52-Week High | $33.61 | $47.20 |
52-Week Low | $24.80 | $11.34 |
Enterprise Value | $37.15B | $5.02B |
Dividend Yield | 1.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Prudential (PUK) trades at $28.88, up 2.09% today, showing strong fundamental momentum with revenue growth from $16.21B in 2024 to $27.4B projected for 2025 and consistent earnings beats. The stock appears undervalued with a P/E of 9.21 and P/S of 1.34, while technical indicators show a bearish trend despite neutral oscillators. Recent news highlights JP Morgan's positive catalyst watch ahead of August earnings and strategic moves in Asian markets.
The outlook remains positive given strong profitability (21.15% ROE) and analyst support (50% buy ratings), but risks include regulatory challenges in Japan and China exposure. Current valuation metrics suggest potential upside if earnings momentum continues, though technical resistance near $29 may limit near-term gains.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
